Vaxcyte Gross Profit from 2010 to 2025

PCVX Stock

USD 73.17 1.49 2.00%

Vaxcyte Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Vaxcyte makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2010-12-31

Previous Quarter

-67.5 M

Current Value

-64.1 M

Quarterly Volatility

27.1 M

Credit Downgrade

Yuan Drop

Covid

Check Vaxcyte financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Vaxcyte's main balance sheet or income statement drivers, such as Interest Income of 115.5 M, Interest Expense of 0.0 or Selling General Administrative of 97.5 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.82. Vaxcyte financial statements analysis is a perfect complement when working with Vaxcyte Valuation or Volatility modules.

Check out the analysis of Vaxcyte Correlation against competitors.

For more information on how to buy Vaxcyte Stock please use our How to Invest in Vaxcyte guide.

Latest Vaxcyte's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Vaxcyte over the last few years. Gross profit is a required income statement account that reflects total revenue of Vaxcyte minus its cost of goods sold. It is profit before Vaxcyte operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Vaxcyte's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Vaxcyte's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (75 M)

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Vaxcyte Gross Profit Regression Statistics

	Arithmetic Mean	(14,459,125)
	Geometric Mean	3,065,512
	Coefficient Of Variation	(187.74)
	Mean Deviation	20,405,953
	Median	(1,232,000)
	Standard Deviation	27,145,489
	Sample Variance	736.9T
	Range	73.8M
	R-Value	(0.69)
	Mean Square Error	408.7T
	R-Squared	0.48
	Significance	0
	Slope	(3,960,065)
	Total Sum of Squares	11053.2T

Vaxcyte Gross Profit History

	2025	-64.1 M
	2024	-67.5 M
	2023	-75 M
	2022	-9.2 M
	2021	-1.8 M
	2020	-1.4 M

Other Fundumenentals of Vaxcyte

Gross Profit Margin

Vaxcyte Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Retained Earnings	Accounts Payable	Long Term Debt	Long Term Debt Total	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Debt	Net Invested Capital	Capital Stock	Net Working Capital	Short Term Debt	Net Receivables	Deferred Long Term Liab
Total Assets		1.0	0.89	-0.97	0.93	-0.62	-0.62	0.77	0.63	0.98	0.92	0.79	-0.55	-0.5	1.0	0.8	0.98	0.46	0.94	0.73
Total Stockholder Equity	1.0		0.89	-0.97	0.93	-0.6	-0.6	0.77	0.6	0.98	0.92	0.79	-0.53	-0.5	1.0	0.8	0.98	0.46	0.94	0.73
Net Tangible Assets	0.89	0.89		-0.94	0.81	-0.76	-0.76	0.92	0.58	0.96	0.98	0.9	-0.72	-0.78	0.9	0.94	0.96	0.74	0.9	0.88
Retained Earnings	-0.97	-0.97	-0.94		-0.89	0.71	0.71	-0.84	-0.7	-0.99	-0.97	-0.87	0.65	0.56	-0.97	-0.89	-0.98	-0.55	-0.98	-0.83
Accounts Payable	0.93	0.93	0.81	-0.89		-0.67	-0.67	0.79	0.58	0.9	0.88	0.66	-0.6	-0.49	0.93	0.76	0.9	0.54	0.83	0.59
Long Term Debt	-0.62	-0.6	-0.76	0.71	-0.67		1.0	-0.88	-0.68	-0.71	-0.8	-0.77	1.0	0.65	-0.63	-0.81	-0.69	-0.83	-0.65	-0.76
Long Term Debt Total	-0.62	-0.6	-0.76	0.71	-0.67	1.0		-0.88	-0.68	-0.71	-0.8	-0.77	1.0	0.65	-0.63	-0.81	-0.69	-0.83	-0.65	-0.76
Capital Surpluse	0.77	0.77	0.92	-0.84	0.79	-0.88	-0.88		0.51	0.85	0.95	0.9	-0.85	-0.72	0.78	0.93	0.84	0.91	0.79	0.88
Total Liab	0.63	0.6	0.58	-0.7	0.58	-0.68	-0.68	0.51		0.65	0.62	0.54	-0.65	-0.31	0.62	0.64	0.63	0.28	0.69	0.56
Total Current Assets	0.98	0.98	0.96	-0.99	0.9	-0.71	-0.71	0.85	0.65		0.97	0.85	-0.65	-0.65	0.98	0.88	1.0	0.59	0.95	0.81
Common Stock	0.92	0.92	0.98	-0.97	0.88	-0.8	-0.8	0.95	0.62	0.97		0.91	-0.76	-0.69	0.93	0.94	0.97	0.74	0.93	0.88
Property Plant Equipment	0.79	0.79	0.9	-0.87	0.66	-0.77	-0.77	0.9	0.54	0.85	0.91		-0.74	-0.6	0.8	0.88	0.85	0.75	0.85	0.98
Current Deferred Revenue	-0.55	-0.53	-0.72	0.65	-0.6	1.0	1.0	-0.85	-0.65	-0.65	-0.76	-0.74		0.65	-0.56	-0.79	-0.63	-0.83	-0.6	-0.74
Net Debt	-0.5	-0.5	-0.78	0.56	-0.49	0.65	0.65	-0.72	-0.31	-0.65	-0.69	-0.6	0.65		-0.51	-0.72	-0.65	-0.78	-0.45	-0.63
Net Invested Capital	1.0	1.0	0.9	-0.97	0.93	-0.63	-0.63	0.78	0.62	0.98	0.93	0.8	-0.56	-0.51		0.81	0.98	0.48	0.94	0.74
Capital Stock	0.8	0.8	0.94	-0.89	0.76	-0.81	-0.81	0.93	0.64	0.88	0.94	0.88	-0.79	-0.72	0.81		0.87	0.78	0.84	0.92
Net Working Capital	0.98	0.98	0.96	-0.98	0.9	-0.69	-0.69	0.84	0.63	1.0	0.97	0.85	-0.63	-0.65	0.98	0.87		0.58	0.94	0.81
Short Term Debt	0.46	0.46	0.74	-0.55	0.54	-0.83	-0.83	0.91	0.28	0.59	0.74	0.75	-0.83	-0.78	0.48	0.78	0.58		0.48	0.76
Net Receivables	0.94	0.94	0.9	-0.98	0.83	-0.65	-0.65	0.79	0.69	0.95	0.93	0.85	-0.6	-0.45	0.94	0.84	0.94	0.48		0.81
Deferred Long Term Liab	0.73	0.73	0.88	-0.83	0.59	-0.76	-0.76	0.88	0.56	0.81	0.88	0.98	-0.74	-0.63	0.74	0.92	0.81	0.76	0.81

Click cells to compare fundamentals

About Vaxcyte Financial Statements

Vaxcyte investors use historical fundamental indicators, such as Vaxcyte's Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Vaxcyte. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Gross Profit	-67.5 M	-64.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Vaxcyte Stock Analysis

When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC